Login Register Cart 0
Review Article

泪膜渗透压，眼表疾病和青光眼：一篇综述。

卷 26, 期 22, 2019

页: [4241 - 4252] 页: 12

弟呕挨: 10.2174/0929867326666190725160621

价格: $65

摘要

青光眼是世界上第二大失明的主要原因，在全球影响着超过6000万人。 为了减少疾病的进展，使用了医学和外科治疗。 两种治疗方法的常见副作用都包括对眼表的一系列修饰，这些眼表被归类为眼表疾病（OSD），其中包括干眼病（DED）。 DED和其他OSD对抗青光眼治疗的成功产生负面影响，并降低了对药物治疗的依从性。 泪膜渗透压（TFO）是一种相对新颖的测试，已成为DED的标志。 本文的目的是根据已发表的TFO数据回顾OSD，DED与青光眼之间的关系，并讨论关于青光眼医源性损害的研究和治疗的未来领域。

关键词: 泪膜渗透压，青光眼，苯扎氯铵，眼表疾病，干眼症，失明。

« Previous Next »
[1]
Quigley, H.A.; Broman, A.T. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol., 2006, 90(3), 262-267.
[http://dx.doi.org/10.1136/bjo.2005.081224] [PMID: 16488940]
[2]
Fogagnolo, P.; Rossetti, L. Medical treatment of glaucoma: present and future. Expert Opin. Investig. Drugs, 2011, 20(7), 947-959.
[http://dx.doi.org/10.1517/13543784.2011.579901] [PMID: 21534887]
[3]
Erb, C.; Gast, U.; Schremmer, D. German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefe’s archive for clinical and experimental ophthalmology =. Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol., 2008, 246(11), 1593-1601.
[http://dx.doi.org/10.1007/s00417-008-0881-9]
[4]
Leung, E.W.; Medeiros, F.A.; Weinreb, R.N. Prevalence of ocular surface disease in glaucoma patients. J. Glaucoma, 2008, 17(5), 350-355.
[http://dx.doi.org/10.1097/IJG.0b013e31815c5f4f] [PMID: 18703943]
[5]
Garcia-Feijoo, J.; Sampaolesi, J.R. A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma. Clin. Ophthalmol., 2012, 6, 441-446.
[PMID: 22536034]
[6]
Baudouin, C. The ocular surface in glaucoma. Cornea, 2009, 28(11), S14-S19.
[http://dx.doi.org/10.1097/ICO.0b013e3181ae8402]
[7]
Gomes, J.A.P.; Azar, D.T.; Baudouin, C.; Efron, N.; Hirayama, M.; Horwath-Winter, J.; Kim, T.; Mehta, J.S.; Messmer, E.M.; Pepose, J.S.; Sangwan, V.S.; Weiner, A.L.; Wilson, S.E.; Wolffsohn, J.S. TFOS DEWS II iatrogenic report. Ocul. Surf., 2017, 15(3), 511-538.
[http://dx.doi.org/10.1016/j.jtos.2017.05.004] [PMID: 28736341]
[8]
Uzunosmanoglu, E.; Mocan, M.C.; Kocabeyoglu, S.; Karakaya, J.; Irkec, M. Meibomian gland dysfunction in patients receiving long-term glaucoma medications. Cornea, 2016, 35(8), 1112-1116.
[http://dx.doi.org/10.1097/ICO.0000000000000838] [PMID: 27055218]
[9]
Baudouin, C.; Hamard, P.; Liang, H.; Creuzot-Garcher, C.; Bensoussan, L.; Brignole, F. Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term. Ophthalmology, 2004, 111(12), 2186-2192.
[http://dx.doi.org/10.1016/j.ophtha.2004.06.023] [PMID: 15582072]
[10]
Pisella, P.J.; Pouliquen, P.; Baudouin, C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br. J. Ophthalmol., 2002, 86(4), 418-423.
[http://dx.doi.org/10.1136/bjo.86.4.418] [PMID: 11914211]
[11]
Dry Eye Workshop 2017 (TFOS DEWS II)
[12]
Downie, L.E. Automated tear film surface quality breakup time as a novel clinical marker for tear hyperosmolarity in dry eye disease. Invest. Ophthalmol. Vis. Sci., 2015, 56(12), 7260-7268.
[http://dx.doi.org/10.1167/iovs.15-17772] [PMID: 26544794]
[13]
Rieger, G. The importance of the precorneal tear film for the quality of optical imaging. Br. J. Ophthalmol., 1992, 76(3), 157-158.
[http://dx.doi.org/10.1136/bjo.76.3.157] [PMID: 1540559]
[14]
Lemp, M.A.; Zimmerman, L.E. Toxic endothelial degeneration in ocular surface disease treated with topical medications containing benzalkonium chloride. Toxic endothelial degeneration in ocular surface disease treated with topical medications containing benzalkonium chloride. Am. J. Ophthalmol., 1988, 105(6), 670-673.
[http://dx.doi.org/10.1016/0002-9394(88)90062-1] [PMID: 3287942]
[15]
Lee, J.H.; Kim, M. Im, Y.S.; Choi, W.; Byeon, S.H.; Lee, H.K. NFAT5 induction and its role in hyperosmolar stressed human limbal epithelial cells. Invest. Ophthalmol. Vis. Sci., 2008, 49(5), 1827-1835.
[http://dx.doi.org/10.1167/iovs.07-1142] [PMID: 18436816]
[16]
Pflugfelder, S.C.; de Paiva, C.S.; Li, D.Q.; Stern, M.E. Epithelial-immune cell interaction in dry eye. Cornea, 2008, 27(Suppl. 1), S9-S11.
[http://dx.doi.org/10.1097/ICO.0b013e31817f4075] [PMID: 18813079]
[17]
Corrales, R.M.; Stern, M.E.; De Paiva, C.S.; Welch, J.; Li, D.Q.; Pflugfelder, S.C. Desiccating stress stimulates expression of matrix metalloproteinases by the corneal epithelium. Invest. Ophthalmol. Vis. Sci., 2006, 47(8), 3293-3302.
[http://dx.doi.org/10.1167/iovs.05-1382] [PMID: 16877394]
[18]
Luo, L.; Li, D.Q.; Doshi, A.; Farley, W.; Corrales, R.M.; Pflugfelder, S.C. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest. Ophthalmol. Vis. Sci., 2004, 45(12), 4293-4301.
[http://dx.doi.org/10.1167/iovs.03-1145] [PMID: 15557435]
[19]
Luo, L.; Li, D.Q.; Corrales, R.M.; Pflugfelder, S.C. Hyperosmolar saline is a proinflammatory stress on the mouse ocular surface. Eye Contact Lens, 2005, 31(5), 186-193.
[http://dx.doi.org/10.1097/01.ICL.0000162759.79740.46] [PMID: 16163009]
[20]
Yeh, S.; Song, X.J.; Farley, W.; Li, D.Q.; Stern, M.E.; Pflugfelder, S.C. Apoptosis of ocular surface cells in experimentally induced dry eye. Invest. Ophthalmol. Vis. Sci., 2003, 44(1), 124-129.
[http://dx.doi.org/10.1167/iovs.02-0581] [PMID: 12506064]
[21]
Gilbard, J.P.; Rossi, S.R.; Heyda, K.G. Tear film and ocular surface changes after closure of the meibomian gland orifices in the rabbit. Ophthalmology, 1989, 96(8), 1180-1186.
[http://dx.doi.org/10.1016/S0161-6420(89)32753-9] [PMID: 2797721]
[22]
Baudouin, C.; Aragona, P.; Messmer, E.M.; Tomlinson, A.; Calonge, M.; Boboridis, K.G.; Akova, Y.A.; Geerling, G.; Labetoulle, M.; Rolando, M. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting. Ocul. Surf., 2013, 11(4), 246-258.
[http://dx.doi.org/10.1016/j.jtos.2013.07.003] [PMID: 24112228]
[23]
Belmonte, C.; Nichols, J.J.; Cox, S.M.; Brock, J.A.; Begley, C.G.; Bereiter, D.A.; Dartt, D.A.; Galor, A.; Hamrah, P.; Ivanusic, J.J.; Jacobs, D.S.; McNamara, N.A.; Rosenblatt, M.I.; Stapleton, F.; Wolffsohn, J.S. TFOS DEWS II pain and sensation report. Ocul. Surf., 2017, 15(3), 404-437.
[http://dx.doi.org/10.1016/j.jtos.2017.05.002] [PMID: 28736339]
[24]
Versura, P.; Profazio, V.; Campos, E.C. Performance of tear osmolarity compared to previous diagnostic tests for dry eye diseases. Curr. Eye Res., 2010, 35(7), 553-564.
[http://dx.doi.org/10.3109/02713683.2010.484557] [PMID: 20597641]
[25]
Sullivan, B.D.; Whitmer, D.; Nichols, K.K.; Tomlinson, A.; Foulks, G.N.; Geerling, G.; Pepose, J.S.; Kosheleff, V.; Porreco, A.; Lemp, M.A. An objective approach to dry eye disease severity. Invest. Ophthalmol. Vis. Sci., 2010, 51(12), 6125-6130.
[http://dx.doi.org/10.1167/iovs.10-5390] [PMID: 20631232]
[26]
Tomlinson, A.; Khanal, S.; Ramaesh, K.; Diaper, C.; McFadyen, A. Tear film osmolarity: determination of a referent for dry eye diagnosis. Invest. Ophthalmol. Vis. Sci., 2006, 47(10), 4309-4315.
[http://dx.doi.org/10.1167/iovs.05-1504] [PMID: 17003420]
[27]
Lemp, M. A.; Bron, A. J.; Baudouin, C.; Benitez Del Castillo, J. M.; Geffen, D.; Tauber, J.; Foulks, G. N.; Pepose, J. S.; Sullivan, B. D. Tear osmolarity in the diagnosis and management of dry eye disease. American journal of ophthalmology, 2011, 151(5), 792-798 e1.
[http://dx.doi.org/10.1016/j.ajo.2010.10.032]
[28]
Sullivan, B.D.; Pepose, J.S.; Foulks, G.N. Progressively increased variation in tear osmolarity mirrors dry eye severity. JAMA Ophthalmol., 2015, 133(12), 1481-1482.
[http://dx.doi.org/10.1001/jamaophthalmol.2015.3854] [PMID: 26469765]
[29]
Available at. www.tearlab.com (accessed on 3rd November 2017).
[30]
Lee, S.Y.; Wong, T.T.; Chua, J.; Boo, C.; Soh, Y.F.; Tong, L. Effect of chronic anti-glaucoma medications and trabeculectomy on tear osmolarity. Eye (Lond.), 2013, 27(10), 1142-1150.
[http://dx.doi.org/10.1038/eye.2013.144] [PMID: 23846375]
[31]
Labbé, A.; Terry, O.; Brasnu, E.; Van Went, C.; Baudouin, C. Tear film osmolarity in patients treated for glaucoma or ocular hypertension. Cornea, 2012, 31(9), 994-999.
[http://dx.doi.org/10.1097/ICO.0b013e31823f8cb6] [PMID: 22710490]
[32]
Halkiadakis, I.; Kontadakis, G.A.; Tsiakou, D.; Patsea, E.; Mitropoulos, P.; Kandarakis, A.S. Effect of glaucoma medication in tear film osmolarity of patients without symptoms of ocular discomfort. J. Ocul. Pharmacol. Ther., 2015, 31(6), 330-334.
[http://dx.doi.org/10.1089/jop.2014.0124] [PMID: 26133056]
[33]
Rasmussen, C.A.; Kaufman, P.L.; Kiland, J.A. Benzalkonium chloride and glaucoma. J. Ocul. Pharmacol. Ther., 2014, 30(2-3), 163-169.
[http://dx.doi.org/10.1089/jop.2013.0174] [PMID: 24205938]
[34]
Clouzeau, C.; Godefroy, D.; Riancho, L.; Rostène, W.; Baudouin, C.; Brignole-Baudouin, F. Hyperosmolarity potentiates toxic effects of benzalkonium chloride on conjunctival epithelial cells in vitro. Mol. Vis., 2012, 18, 851-863.
[PMID: 22529703]
[35]
Png, E.; Samivelu, G.K.; Yeo, S.H.; Chew, J.; Chaurasia, S.S.; Tong, L. Hyperosmolarity-mediated mitochondrial dysfunction requires Transglutaminase-2 in human corneal epithelial cells. J. Cell. Physiol., 2011, 226(3), 693-699.
[http://dx.doi.org/10.1002/jcp.22389] [PMID: 20717931]
[36]
Luo, L.; Li, D.Q.; Pflugfelder, S.C. Hyperosmolarity-induced apoptosis in human corneal epithelial cells is mediated by cytochrome c and MAPK pathways. Cornea, 2007, 26(4), 452-460.
[http://dx.doi.org/10.1097/ICO.0b013e318030d259] [PMID: 17457195]
[37]
Xiong, C.; Chen, D.; Liu, J.; Liu, B.; Li, N.; Zhou, Y.; Liang, X.; Ma, P.; Ye, C.; Ge, J.; Wang, Z. A rabbit dry eye model induced by topical medication of a preservative benzalkonium chloride. Invest. Ophthalmol. Vis. Sci., 2008, 49(5), 1850-1856.
[http://dx.doi.org/10.1167/iovs.07-0720] [PMID: 18436819]
[38]
Lin, Z.; Liu, X.; Zhou, T.; Wang, Y.; Bai, L.; He, H.; Liu, Z. A mouse dry eye model induced by topical administration of benzalkonium chloride. Mol. Vis., 2011, 17, 257-264.
[PMID: 21283525]
[39]
Debbasch, C.; Brignole, F.; Pisella, P.J.; Warnet, J.M.; Rat, P.; Baudouin, C. Quaternary ammoniums and other preservatives’ contribution in oxidative stress and apoptosis on Chang conjunctival cells. Invest. Ophthalmol. Vis. Sci., 2001, 42(3), 642-652.
[PMID: 11222522]
[40]
Guenoun, J.M.; Baudouin, C.; Rat, P.; Pauly, A.; Warnet, J.M.; Brignole-Baudouin, F. In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells. Invest. Ophthalmol. Vis. Sci., 2005, 46(12), 4594-4599.
[http://dx.doi.org/10.1167/iovs.05-0776] [PMID: 16303954]
[41]
Pauly, A.; Meloni, M.; Brignole-Baudouin, F.; Warnet, J.M.; Baudouin, C. Multiple endpoint analysis of the 3D-reconstituted corneal epithelium after treatment with benzalkonium chloride: early detection of toxic damage. Invest. Ophthalmol. Vis. Sci., 2009, 50(4), 1644-1652.
[http://dx.doi.org/10.1167/iovs.08-2992] [PMID: 19168896]
[42]
Liang, H.; Baudouin, C.; Pauly, A.; Brignole-Baudouin, F. Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. Br. J. Ophthalmol., 2008, 92(9), 1275-1282.
[http://dx.doi.org/10.1136/bjo.2008.138768] [PMID: 18723745]
[43]
Baudouin, C. Side effects of antiglaucomatous drugs on the ocular surface. Curr. Opin. Ophthalmol., 1996, 7(2), 80-86.
[http://dx.doi.org/10.1097/00055735-199604000-00014] [PMID: 10163327]
[44]
Rolando, M.; Terragna, F.; Giordano, G.; Calabria, G. Conjunctival surface damage distribution in keratoconjunctivitis sicca. An impression cytology study. Ophthalmologica. Journal international d’ophtalmologie. International journal of ophthalmology. Z. Augenheilkd., 1990, 200(4), 170-176.
[45]
Kahook, M.Y.; Noecker, R. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops. Adv. Ther., 2008, 25(8), 743-751.
[http://dx.doi.org/10.1007/s12325-008-0078-y] [PMID: 18670744]
[46]
Barabino, S.; Antonelli, S.; Cimbolini, N.; Mauro, V.; Bouzin, M. The effect of preservatives and antiglaucoma treatments on the ocular surface of mice with dry eye. Invest. Ophthalmol. Vis. Sci., 2014, 55(10), 6499-6504.
[http://dx.doi.org/10.1167/iovs.14-14548] [PMID: 25205861]
[47]
Baudouin, C.; Liang, H.; Hamard, P.; Riancho, L.; Creuzot-Garcher, C.; Warnet, J.M.; Brignole-Baudouin, F. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology, 2008, 115(1), 109-115.
[http://dx.doi.org/10.1016/j.ophtha.2007.01.036] [PMID: 17532048]
[48]
Ciancaglini, M.; Carpineto, P.; Agnifili, L.; Nubile, M.; Fasanella, V.; Lanzini, M.; Calienno, R.; Mastropasqua, L. An in vivo confocal microscopy and impression cytology analysis of preserved and unpreserved levobunolol-induced conjunctival changes. Eur. J. Ophthalmol., 2008, 18(3), 400-407.
[http://dx.doi.org/10.1177/112067210801800314] [PMID: 18465723]
[49]
Frezzotti, P.; Fogagnolo, P.; Haka, G.; Motolese, I.; Iester, M.; Bagaglia, S.A.; Mittica, P.; Menicacci, C.; Rossetti, L.; Motolese, E. In vivo confocal microscopy of conjunctiva in preservative-free timolol 0.1% gel formulation therapy for glaucoma. Acta Ophthalmol., 2014, 92(2), e133-e140.
[http://dx.doi.org/10.1111/aos.12261] [PMID: 24020826]
[50]
Ranno, S.; Fogagnolo, P.; Rossetti, L.; Orzalesi, N.; Nucci, P. Changes in corneal parameters at confocal microscopy in treated glaucoma patients. Clin. Ophthalmol., 2011, 5, 1037-1042.
[http://dx.doi.org/10.2147/OPTH.S22874] [PMID: 21845031]
[51]
Iester, M.; Telani, S.; Frezzotti, P.; Motolese, I.; Figus, M.; Fogagnolo, P.; Perdicchi, A. Beta-blocker study group. Ocular surface changes in glaucomatous patients treated with and without preservatives beta-blockers. J. Ocul. Pharmacol. Ther., 2014, 30(6), 476-481.
[http://dx.doi.org/10.1089/jop.2013.0216] [PMID: 24787056]
[52]
Hoh, H. [Preservative-free timolol eye drops--surface-anesthetic effect and local compatibility Ophthalmologica. Journal international d’ophtalmologie. International journal of ophthalmology. Z. Augenheilkd., 1990, 200(2), 89-97.
[53]
Katz, G.; Springs, C.L.; Craven, E.R.; Montecchi-Palmer, M. Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost. Clin. Ophthalmol., 2010, 4, 1253-1261.
[http://dx.doi.org/10.2147/OPTH.S14113] [PMID: 21151330]
[54]
Janulevičienė, I.; Derkač, I.; Grybauskiene, L.; Paulauskaitė, R.; Gromnickaite, R.; Kuzmienė, L. Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma. Clin. Ophthalmol., 2012, 6, 103-109.
[http://dx.doi.org/10.2147/OPTH.S28104] [PMID: 22275814]
[55]
Mietz, H.; Niesen, U.; Krieglstein, G.K. The effect of preservatives and antiglaucomatous medication on the histopathology of the conjunctiva. Graefe’s archive for clinical and experimental ophthalmology =. Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol., 1994, 232(9), 561-565.
[http://dx.doi.org/10.1007/BF00182000]
[56]
Coleiro, J.A.; Sigurdsson, H.; Lockyer, J.A. Follicular conjunctivitis on Dipivefrin therapy for glaucoma. Eye (Lond.), 1988, 2(Pt 4), 440-442.
[http://dx.doi.org/10.1038/eye.1988.80] [PMID: 3253137]
[57]
Liesegang, T.J. Bulbar conjunctival follicles associated with dipivefrin therapy. Ophthalmology, 1985, 92(2), 228-233.
[http://dx.doi.org/10.1016/S0161-6420(85)34048-4] [PMID: 3982802]
[58]
Fraunfelder, F.W. Corneal toxicity from topical ocular and systemic medications. Cornea, 2006, 25(10), 1133-1138.
[http://dx.doi.org/10.1097/01.ico.0000240084.27663.fd] [PMID: 17172885]
[59]
Berdy, G.J.; Abelson, M.B.; Smith, L.M.; George, M.A. Preservative-free artificial tear preparations. Assessment of corneal epithelial toxic effects. Arch. Ophthalmol., 1992, 110(4), 528-532.
[http://dx.doi.org/10.1001/archopht.1992.01080160106043] [PMID: 1562263]
[60]
Becquet, F.; Goldschild, M.; Moldovan, M.S.; Ettaiche, M.; Gastaud, P.; Baudouin, C. Histopathological effects of topical ophthalmic preservatives on rat corneoconjunctival surface. Curr. Eye Res., 1998, 17(4), 419-425.
[http://dx.doi.org/10.1080/02713689808951223] [PMID: 9561834]
[61]
Sherwood, M.B.; Grierson, I.; Millar, L.; Hitchings, R.A. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon’s capsule in glaucomatous patients. Ophthalmology, 1989, 96(3), 327-335.
[http://dx.doi.org/10.1016/S0161-6420(89)32888-0] [PMID: 2710524]
[62]
Mullins, R.J.; Lones, R.; Dutta, B. Lichenoid drug eruption secondary to topical timolol and dorzolamide eye-drops. Australas. J. Dermatol., 2004, 45(2), 151-152.
[http://dx.doi.org/10.1111/j.1440-0960.2004.00074.x] [PMID: 15068470]
[63]
Holdiness, M. R. Contact dermatitis to topical drugs for glaucoma. American journal of contact dermatitis: official journal of the American Contact Dermatitis Society, 2001, 12(4), 217-9.
[64]
Turaçli, E.; Budak, K.; Kaur, A.; Mizrak, B.; Ekinci, C. The effects of long-term topical glaucoma medication on conjunctival impression cytology. Int. Ophthalmol., 1997, 21(1), 27-33.
[http://dx.doi.org/10.1023/A:1005892426045] [PMID: 9298420]
[65]
Pisella, P.J.; Debbasch, C.; Hamard, P.; Creuzot-Garcher, C.; Rat, P.; Brignole, F.; Baudouin, C. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest. Ophthalmol. Vis. Sci., 2004, 45(5), 1360-1368.
[http://dx.doi.org/10.1167/iovs.03-1067] [PMID: 15111589]
[66]
Mietz, H.; Schlötzer-Schrehardt, U.; Strassfeld, C.; Krieglstein, G.K. Effect of latanoprost and timolol on the histopathology of the rabbit conjunctiva. Invest. Ophthalmol. Vis. Sci., 2001, 42(3), 679-687.
[PMID: 11222527]
[67]
Baudouin, C.; Riancho, L.; Warnet, J.M.; Brignole, F. In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. Invest. Ophthalmol. Vis. Sci., 2007, 48(9), 4123-4128.
[http://dx.doi.org/10.1167/iovs.07-0266] [PMID: 17724196]
[68]
Taguri, A.H.; Khan, M.A.; Sanders, R. Marginal keratitis: an uncommon form of topical dorzolamide allergy. Am. J. Ophthalmol., 2000, 130(1), 120-122.
[http://dx.doi.org/10.1016/S0002-9394(00)00478-5] [PMID: 11004272]
[69]
Fogagnolo, P.; Dipinto, A.; Vanzulli, E.; Maggiolo, E.; De Cilla’, S.; Autelitano, A.; Rossetti, L. A 1-year randomized study of the clinical and confocal effects of tafluprost and latanoprost in newly diagnosed glaucoma patients. Adv. Ther., 2015, 32(4), 356-369.
[http://dx.doi.org/10.1007/s12325-015-0205-5] [PMID: 25893514]
[70]
Baudouin, C. Ocular surface and external filtration surgery: mutual relationships. Dev. Ophthalmol., 2012, 50, 64-78.
[http://dx.doi.org/10.1159/000334791] [PMID: 22517174]
[71]
Coppens, G.; Maudgal, P. Corneal complications of intraoperative Mitomycin C in glaucoma surgery. Bull. Soc. Belge Ophtalmol., 2010, (314), 19-23.
[PMID: 20480747]
[72]
Hau, S.; Barton, K. Corneal complications of glaucoma surgery. Curr. Opin. Ophthalmol., 2009, 20(2), 131-136.
[http://dx.doi.org/10.1097/ICU.0b013e328325a54b] [PMID: 19240546]
[73]
Sauder, G.; Jonas, J.B. Limbal stem cell deficiency after subconjunctival mitomycin C injection for trabeculectomy. Am. J. Ophthalmol., 2006, 141(6), 1129-1130.
[http://dx.doi.org/10.1016/j.ajo.2006.01.018] [PMID: 16765685]
[74]
Wilson, S.E.; Netto, M.; Ambrósio, R., Jr Corneal cells: chatty in development, homeostasis, wound healing, and disease. Am. J. Ophthalmol., 2003, 136(3), 530-536.
[http://dx.doi.org/10.1016/S0002-9394(03)00085-0] [PMID: 12967809]
[75]
Shimazaki, J.; Hanada, K.; Yagi, Y.; Yamagami, J.; Ishioka, M.; Shimmura, S.; Tsubota, K. Changes in ocular surface caused by antiglaucomatous eyedrops: prospective, randomised study for the comparison of 0.5% timolol v 0.12% unoprostone. Br. J. Ophthalmol., 2000, 84(11), 1250-1254.
[http://dx.doi.org/10.1136/bjo.84.11.1250] [PMID: 11049949]
[76]
Dupps, W.J., Jr; Wilson, S.E. Biomechanics and wound healing in the cornea. Exp. Eye Res., 2006, 83(4), 709-720.
[http://dx.doi.org/10.1016/j.exer.2006.03.015] [PMID: 16720023]
[77]
Soong, H.K.; Quigley, H.A. Dellen associated with filtering blebs. Arch. Ophthalmol., 1983, 101(3), 385-387.
[http://dx.doi.org/10.1001/archopht.1983.01040010385006] [PMID: 6830488]
[78]
Goldberg, I.; Graham, S.L.; Crowston, J.G.; d’Mellow, G. Australian and New Zealand Glaucoma Interest Group. Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease. Clin. Exp. Ophthalmol., 2015, 43(3), 214-220.
[http://dx.doi.org/10.1111/ceo.12431] [PMID: 25196488]
[79]
Aragona, P.; Papa, V.; Micali, A.; Santocono, M.; Milazzo, G. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br. J. Ophthalmol., 2002, 86(2), 181-184.
[http://dx.doi.org/10.1136/bjo.86.2.181] [PMID: 11815344]
[80]
Pauloin, T.; Dutot, M.; Warnet, J. M.; Rat, P. In vitro modulation of preservative toxicity: high molecular weight hyaluronan decreases apoptosis and oxidative stress induced by benzalkonium chloride. European journal of pharmaceutical sciences: official journal of the European Federation for Pharmaceutical Sciences, 2008, 34(4-5), 263-73.
[81]
Debbasch, C.; De La Salle, S.B.; Brignole, F.; Rat, P.; Warnet, J.M.; Baudouin, C. Cytoprotective effects of hyaluronic acid and Carbomer 934P in ocular surface epithelial cells. Invest. Ophthalmol. Vis. Sci., 2002, 43(11), 3409-3415.
[PMID: 12407150]
[82]
Yu, F.; Liu, X.; Zhong, Y.; Guo, X.; Li, M.; Mao, Z.; Xiao, H.; Yang, S. Sodium hyaluronate decreases ocular surface toxicity induced by benzalkonium chloride-preserved latanoprost: an in vivo study. Invest. Ophthalmol. Vis. Sci., 2013, 54(5), 3385-3393.
[http://dx.doi.org/10.1167/iovs.12-11181] [PMID: 23620425]
[83]
Iester, M.; Oddone, F.; Fogagnolo, P.; Frezzotti, P.; Figus, M. Confocal Microscopy Study, G., Changes in the morphological and functional patterns of the ocular surface in patients treated with prostaglandin analogues after the use of TSP 0.5%(R) preservative-free eyedrops: a prospective, multicenter study. Ophthalmic Res., 2014, 51(3), 146-152.
[http://dx.doi.org/10.1159/000357100] [PMID: 24557328]
[84]
Monaco, G.; Cacioppo, V.; Consonni, D.; Troiano, P. Effects of osmoprotection on symptoms, ocular surface damage, and tear film modifications caused by glaucoma therapy. Eur. J. Ophthalmol., 2011, 21(3), 243-250.
[http://dx.doi.org/10.5301/EJO.2010.5730] [PMID: 20872359]
[85]
Batra, R.; Tailor, R.; Mohamed, S. Ocular surface disease exacerbated glaucoma: optimizing the ocular surface improves intraocular pressure control. J. Glaucoma, 2014, 23(1), 56-60.
[http://dx.doi.org/10.1097/IJG.0b013e318264cd68] [PMID: 22828007]
[86]
Sullivan, B.D.; Crews, L.A.; Sönmez, B.; de la Paz, M.F.; Comert, E.; Charoenrook, V.; de Araujo, A.L.; Pepose, J.S.; Berg, M.S.; Kosheleff, V.P.; Lemp, M.A. Clinical utility of objective tests for dry eye disease: variability over time and implications for clinical trials and disease management. Cornea, 2012, 31(9), 1000-1008.
[http://dx.doi.org/10.1097/ICO.0b013e318242fd60] [PMID: 22475641]
[87]
Bron, A.J.; Tomlinson, A.; Foulks, G.N.; Pepose, J.S.; Baudouin, C.; Geerling, G.; Nichols, K.K.; Lemp, M.A. Rethinking dry eye disease: a perspective on clinical implications. Ocul. Surf., 2014, 12(2)(Suppl.), S1-S31.
[http://dx.doi.org/10.1016/j.jtos.2014.02.002] [PMID: 24725379]
[88]
Sullivan, B.D.; Crews, L.A.; Messmer, E.M.; Foulks, G.N.; Nichols, K.K.; Baenninger, P.; Geerling, G.; Figueiredo, F.; Lemp, M.A. Correlations between commonly used objective signs and symptoms for the diagnosis of dry eye disease: clinical implications. Acta Ophthalmol., 2014, 92(2), 161-166.
[http://dx.doi.org/10.1111/aos.12012] [PMID: 23279964]

Rights & Permissions Print Cite
Article Metrics
63
6
© 2024 Bentham Science Publishers | Privacy Policy